Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.6K
Introduction to Hemostasis01:05

Introduction to Hemostasis

13.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
13.4K
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

5
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
5
Rh Blood Group01:19

Rh Blood Group

4.2K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunopeptidomics of blood coagulation factor IX: a core peptide derived from the protease domain is promiscuously presented on HLA-DR.

Research and practice in thrombosis and haemostasis·2026
Same author

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026
Same author

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Blood loss due to diagnostic testing in extremely preterm infants in 22 European countries: a prospective observational study.

EClinicalMedicine·2026
Same author

The Diagnosis and Evaluation of Women and Girls with Hemophilia and Hemophilia Carriers: Guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Psychometric evaluation of Patient-Reported Outcomes Measurement Information System (PROMIS) in pediatric sickle cell disease in Europe.

European journal of pediatrics·2026

Related Experiment Video

Updated: Apr 21, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K

[Haemophilia].

Janneke I Loomans1, Janske Lock, Marjolein Peters

  • 1Academisch Medisch Centrum, Emma Kinderziekenhuis, Amsterdam.

Nederlands Tijdschrift Voor Geneeskunde
|October 30, 2014
PubMed
Summary
This summary is machine-generated.

Haemophilia, an inherited bleeding disorder, results from low clotting factors VIII or IX. Treatment involves factor concentrates, but complications like antibodies can arise, necessitating specialized care.

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.3K
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

2.1K

Related Experiment Videos

Last Updated: Apr 21, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.3K
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

2.1K

Area of Science:

  • Hematology
  • Genetics
  • Pharmacology

Background:

  • Haemophilia is an X-linked inherited disorder affecting blood clotting due to deficiencies in factor VIII (haemophilia A) or factor IX (haemophilia B).
  • Prevalence is approximately 1 in 5000 males, leading to spontaneous bleeding and excessive blood loss after injury.
  • Carrier females may exhibit mild symptoms due to reduced factor levels.

Purpose of the Study:

  • To provide a comprehensive overview of haemophilia, including its genetic basis, clinical manifestations, and current management strategies.
  • To highlight potential complications associated with haemophilia and its treatment.
  • To emphasize the importance of specialized care for haemophilia patients.

Main Methods:

  • Review of existing literature on haemophilia genetics, pathophysiology, and treatment modalities.
  • Analysis of standard treatment protocols, including prophylactic factor concentrate administration.
  • Identification and discussion of common complications, such as inhibitor antibody formation.

Main Results:

  • Deficiency in clotting factors VIII or IX causes bleeding disorders.
  • Prophylactic factor concentrates are standard for severe haemophilia in children.
  • NSAIDs can cause life-threatening bleeding; inhibitor antibodies are a major treatment complication.

Conclusions:

  • Haemophilia management requires a multidisciplinary team approach.
  • Specialized treatment centers are crucial for optimal patient care.
  • Understanding genetic factors and potential complications is key to effective haemophilia treatment.